Quarterly report
Open the filing on sec.gov
Hemab Therapeutics Holdings, Inc. (COAG)
Nasdaq: COAG · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2026
The companyas filed
Revenuen/a
Net incomen/a
Earnings per sharen/a
Operating cash flown/a
Cashn/a
Debtn/a
Shareholders’ equityn/a
Shares, dilutedn/a
Return on equityn/a
The recordfrom its filings
Filings in 202653
Newest filingNov 10 · 10-Q
Annual reportn/a
Quarterly reportNov 10, 2026
Next report due10-K by Mar 31
Insider sales, 12 months$0.00
Insider buys, 12 months$55.5M
Patents grantedn/a
Filer categoryNon-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
The record holds no annual figures yet.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider holding, initial
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Quarterly report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.